Prohibits former employees of certain health agencies from serving on boards of entities involved in drug, biological product, or device development and research within 8 years of their service ending.
Defines “covered health agencies” to include the National Institutes of Health, the Food and Drug Administration, and the Centers for Disease Control and Prevention.
Defines “top official” as any executive branch employee at or above GS-13 or anyone with authority over drug, biological product, or device use authorization.
Imposes penalties for former covered health agency employees who profit from a drug, biological product, or device they were involved in approving for grant applications, including a $250,000 civil penalty and imprisonment.
Amends penalties section to include violations of the new prohibitions.
Applies the new rules to individuals whose service ends after the enactment of the Act, with a special compliance period for those whose service ended before enactment.
Prohibits top officials from applying for patents related to their work during and after their employment, with specific rules for inventions made during and outside of their official duties.
Requires top officials and their spouses to disclose any ownership or interest in relevant patents within set timeframes after the Act’s enactment or after becoming a top official.
